Syros Pharmaceuticals Inc (NASDAQ:SYRS) Director Sells $250,000.00 in Stock

Syros Pharmaceuticals Inc (NASDAQ:SYRS) Director Richard A. Young sold 25,000 shares of Syros Pharmaceuticals stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a filing with the SEC, which is available through this link.

SYRS traded up $0.09 during midday trading on Monday, hitting $11.17. The company had a trading volume of 199,458 shares, compared to its average volume of 179,801. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.11 and a current ratio of 8.11. The company has a market capitalization of $418.02 million, a PE ratio of -5.85 and a beta of 1.94. Syros Pharmaceuticals Inc has a twelve month low of $5.17 and a twelve month high of $13.16. The firm’s 50-day simple moving average is $8.37 and its 200-day simple moving average is $7.41.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.06). The company had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.42 million. Syros Pharmaceuticals had a negative net margin of 3,137.55% and a negative return on equity of 79.79%. As a group, sell-side analysts anticipate that Syros Pharmaceuticals Inc will post -1.94 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of Montreal Can grew its position in shares of Syros Pharmaceuticals by 11,319.2% during the 2nd quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock worth $27,000 after buying an additional 2,943 shares during the period. BNP Paribas Arbitrage SA acquired a new stake in shares of Syros Pharmaceuticals during the 1st quarter worth approximately $48,000. A.R.T. Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals during the 2nd quarter worth approximately $119,000. Susquehanna International Group LLP acquired a new stake in shares of Syros Pharmaceuticals during the 2nd quarter worth approximately $133,000. Finally, Bank of America Corp DE grew its position in shares of Syros Pharmaceuticals by 205.9% during the 4th quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after buying an additional 11,711 shares during the period. Hedge funds and other institutional investors own 69.66% of the company’s stock.

Several equities analysts recently issued reports on the stock. HC Wainwright reissued a “neutral” rating on shares of Syros Pharmaceuticals in a report on Thursday, May 2nd. Roth Capital assumed coverage on shares of Syros Pharmaceuticals in a report on Friday, July 12th. They set a “buy” rating and a $17.00 price target for the company. Wedbush reissued an “outperform” rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a report on Thursday, April 25th. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 26th. Finally, BidaskClub raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, July 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.03.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Featured Article: Why is the price target of stocks important?

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.